[{"id":"0e10acf9-5a67-407c-ab46-05c9fe46a0db","acronym":"","url":"https://clinicaltrials.gov/study/NCT00710710","created_at":"2021-07-05T16:04:35.612Z","updated_at":"2024-07-02T16:36:11.025Z","phase":"Phase 2","brief_title":"Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer","source_id_and_acronym":"NCT00710710","lead_sponsor":"Boehringer Ingelheim","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BI2536"],"overall_status":"Completed","enrollment":" Enrollment 89","initiation":"Initiation: 08/01/2006","start_date":" 08/01/2006","primary_txt":" Primary completion: 10/14/2008","primary_completion_date":" 10/14/2008","study_txt":" Completion: 10/14/2008","study_completion_date":" 10/14/2008","last_update_posted":"2022-05-04"}]